Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 5/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | DRD4 | P21917 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | SMO | Q99835 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11923385 | 0.96 | SIGMAR1 (0.79) | SIGMAR1MAPTL3MBTL1DRD4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11213408 | 0.94 | SIGMAR1 (0.77) | SIGMAR1MAPTL3MBTL1DRD4ALDH1A1 | |
| SCHEMBL8729399 | 0.91 | SIGMAR1 (0.67) | SIGMAR1MAPTL3MBTL1ALDH1A1TDP1 | |
| SCHEMBL2881069 | 0.89 | DRD4 (0.64) | SIGMAR1MAPTL3MBTL1DRD4ALDH1A1 | |
| SCHEMBL28217942 | 0.85 | SIGMAR1 (1.00) | SIGMAR1ALDH1A1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL15937935 | 0.84 | DRD4 (0.69) | SIGMAR1MAPTL3MBTL1DRD4ALDH1A1 | |
| SCHEMBL3708916 | 0.83 | ALDH1A1 (0.67) | SIGMAR1MAPTL3MBTL1ALDH1A1GLA | |
| SCHEMBL6030381 | 0.82 | ALDH1A1 (0.72) | SIGMAR1MAPTDRD4ALDH1A1MAPK1 | |
| SCHEMBL6030554 | 0.82 | SIGMAR1 (0.62) | SIGMAR1MAPTDRD4ALDH1A1TDP1 | |
| SCHEMBL2881058 | 0.82 | PPARD (0.63) | SIGMAR1MAPTDRD4MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750012-B2 | Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation | DECODE GENETICS EHF (IS) | 2010-07-06 | — | — | US | disclosed |
| US-7750012-B2 | Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation | DECODE GENETICS EHF (IS) | 2010-07-06 | — | — | US | disclosed |
| US-7750012-B2 | Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation | DECODE GENETICS EHF (IS) | 2010-07-06 | — | — | US | disclosed |
| EP-1968961-A2 | BIARYL NITROGEN HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | Decode Genetics EHF (IS) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007078335-A2 | BIARYL NITROGEN HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS, EHF. (IS) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007078335-A2 | BIARYL NITROGEN HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS, EHF. (IS) | 2007-07-12 | — | — | WO | disclosed |
| US-20070149544-A1 | BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149544-A1 | BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149544-A1 | BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149544-A1 | BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTC4S, LTB4R | SIGMAR1 2860/4885MAPT 4389/4885L3MBTL1 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.